These in vitro results are in line with findings observed in animal models, which have demonstrated the therapeutic action of PACAP in motor and behavioral disturbances of PD (Reglodi et al., 2004a,b; Maasz et al., 2017). Here, ADCYAP1 is linked to Parkinson disease.